HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction Results of Q2 2024, including settlement of long-running arbitration.

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights Results of Q2 2024, including settlement of long-running arbitration.

Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors.